Aim To predict the long-term benefits and economic costs of the improvements in haemophilia care in China demonstrated by increasing use of prophylaxi......
Introduction Studying the pathological changes of ligaments in patients with haemophilic arthritis (HA) has important significance for guiding the rel......
Introduction Omfiloctocog alfa, the first China-developed recombinant factor VIII (FVIII), demonstrated efficacy and safety of prophylaxis in previous......
Introduction Microstructural alterations of brain structure in haemophilic boys were found in our previous study. Aim We investigated alterations of b......
Introduction Current treatment of severe haemophilia A includes prophylaxis with factor VIII (FVIII) replacement. The supply of plasma-derived FVIII i......
Introduction As standard care of severe haemophilia A (SHA), prophylaxis should be individualised. Aim This study aimed to investigate the effectivene......
Introduction Clarifying the links between iron and FGF23, SOX9 expression in chondrocytes would be helpful for comprehending articular cartilage degra......
Introduction SCT800 is a recombinant human B-domain-deleted coagulation factor VIII (BDDrFVIII) developed in China. Aim To evaluate the repeat pharmac......
Introduction Clinical practice showed that patients with haemophilia (PwH) with bony ankylosed end-stage haemophilic arthropathy knees reported milder......
Background The traditional weight-based dosing regimen can lead to under- or overdosage due to the interindividual variability of pharmacokinetic (PK)......
